Oncopeptides AB banner

Oncopeptides AB
STO:ONCO

Watchlist Manager
Oncopeptides AB Logo
Oncopeptides AB
STO:ONCO
Watchlist
Price: 1.576 SEK -0.13% Market Closed
Market Cap: kr639.9m

Wall Street
Price Targets

ONCO Price Targets Summary
Oncopeptides AB

Wall Street analysts forecast ONCO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ONCO is 2.695 SEK with a low forecast of 2.668 SEK and a high forecast of 2.774 SEK.

Lowest
Price Target
2.668 SEK
69% Upside
Average
Price Target
2.695 SEK
71% Upside
Highest
Price Target
2.774 SEK
76% Upside
Oncopeptides AB Competitors:
Price Targets
BTBT
Bit Digital Inc
242% Upside

Revenue
Forecast

N/A
Past Growth
106% / Year
Estimated Growth
Estimates Accuracy
-26%
Average Miss
N/A
Past Growth
106% / Year
Estimated Growth
Estimates Accuracy
-26%
Average Miss

The compound annual growth rate of Oncopeptides AB's revenue for the next 2 years is 106%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-67%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-67%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ONCO's stock price target?
Price Target
2.695 SEK

According to Wall Street analysts, the average 1-year price target for ONCO is 2.695 SEK with a low forecast of 2.668 SEK and a high forecast of 2.774 SEK.

What is Oncopeptides AB's Revenue forecast?
Projected CAGR
106%

The compound annual growth rate of Oncopeptides AB's revenue for the next 2 years is 106%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett